These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 25488087)
21. Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis. Bodelon C; Pfeiffer RM; Buys SS; Black A; Sherman ME J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25217774 [TBL] [Abstract][Full Text] [Related]
22. Origin of ovarian cancer may have implications for screening. Tuma RS J Natl Cancer Inst; 2010 Jan; 102(1):11-3. PubMed ID: 20023201 [No Abstract] [Full Text] [Related]
23. Enhanced ovarian cancer detection. Two-test combo may identify disease early enough to cure it. Duke Med Health News; 2009 Jun; 15(6):8-9. PubMed ID: 19575525 [No Abstract] [Full Text] [Related]
24. Update on ovarian cancer screening. Munkarah A; Chatterjee M; Tainsky MA Curr Opin Obstet Gynecol; 2007 Feb; 19(1):22-6. PubMed ID: 17218847 [TBL] [Abstract][Full Text] [Related]
25. Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations. Lentz SE; Powell CB; Haque R; Armstrong MA; Anderson M; Liu Y; Jiang W; Chillemi G; Shaw S; Alvarado MM; Kushi LH; Skates SJ Gynecol Oncol; 2020 Dec; 159(3):804-810. PubMed ID: 33012551 [TBL] [Abstract][Full Text] [Related]
26. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer. Gu Z; He Y; Zhang Y; Chen M; Song K; Huang Y; Li Q; Di W J Transl Med; 2018 May; 16(1):114. PubMed ID: 29716620 [TBL] [Abstract][Full Text] [Related]
27. Risk of malignancy in sonographically confirmed ovarian tumors. Miller RW; Ueland FR Clin Obstet Gynecol; 2012 Mar; 55(1):52-64. PubMed ID: 22343229 [TBL] [Abstract][Full Text] [Related]
28. Biomarkers and Strategies for Early Detection of Ovarian Cancer. Bast RC; Lu Z; Han CY; Lu KH; Anderson KS; Drescher CW; Skates SJ Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2504-2512. PubMed ID: 33051337 [TBL] [Abstract][Full Text] [Related]
29. Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations. Haque R; Skates SJ; Armstrong MA; Lentz SE; Anderson M; Jiang W; Alvarado MM; Chillemi G; Shaw SF; Kushi LH; Powell CB Gynecol Oncol; 2020 May; 157(2):521-528. PubMed ID: 32145911 [TBL] [Abstract][Full Text] [Related]
30. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses. Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587 [TBL] [Abstract][Full Text] [Related]
31. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390 [TBL] [Abstract][Full Text] [Related]
32. Potential role of HE4 in multimodal screening for epithelial ovarian cancer. Urban N; Thorpe JD; Bergan LA; Forrest RM; Kampani AV; Scholler N; O'Briant KC; Anderson GL; Cramer DW; Berg CD; McIntosh MW; Hartge P; Drescher CW J Natl Cancer Inst; 2011 Nov; 103(21):1630-4. PubMed ID: 21917606 [TBL] [Abstract][Full Text] [Related]
33. Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival. Temkin SM; Miller EA; Samimi G; Berg CD; Pinsky P; Minasian L Eur J Cancer; 2017 Dec; 87():182-188. PubMed ID: 29156299 [TBL] [Abstract][Full Text] [Related]
34. Recent developments in ovarian cancer screening. Menon U; Jacobs IJ Curr Opin Obstet Gynecol; 2000 Feb; 12(1):39-42. PubMed ID: 10752515 [TBL] [Abstract][Full Text] [Related]
36. Early detection of familial ovarian cancer. Dørum A; Kristensen GB; Abeler VM; Tropé CG; Møller P Eur J Cancer; 1996 Sep; 32A(10):1645-51. PubMed ID: 8983269 [TBL] [Abstract][Full Text] [Related]
37. Ovarian status in healthy postmenopausal women. Healy DL; Bell R; Robertson DM; Jobling T; Oehler MK; Edwards A; Shekleton P; Oldham J; Piessens S; Teoh M; Mamers P; Taylor N; Walker F Menopause; 2008; 15(6):1109-14. PubMed ID: 18536617 [TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts. Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055 [TBL] [Abstract][Full Text] [Related]
39. A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. Russell MR; Graham C; D'Amato A; Gentry-Maharaj A; Ryan A; Kalsi JK; Ainley C; Whetton AD; Menon U; Jacobs I; Graham RLJ Br J Cancer; 2017 Aug; 117(5):666-674. PubMed ID: 28664912 [TBL] [Abstract][Full Text] [Related]
40. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Bast RC Trans Am Clin Climatol Assoc; 2004; 115():233-47; discussion 247-8. PubMed ID: 17060970 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]